Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$14.40 +4.2%	$13.91	$7.86 ▼ $17.75	$1.65B	1.77	2.23 million shs	3.17 million shs
LEGN Legend Biotech	$33.85 -0.4%	$32.32	$27.34 ▼ $60.87	$6.25B	0.13	1.34 million shs	803,708 shs
TGTX TG Therapeutics	$36.56 +1.5%	$37.15	$16.65 ▼ $46.48	$5.72B	1.94	2.94 million shs	1.58 million shs
TLX Telix Pharmaceuticals	$16.39 -4.4%	$17.06	$13.61 ▼ $30.36	$5.80B	N/A	26,944 shs	70,997 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	0.00%	+2.90%	-1.14%	-20.07%	+62.78%
LEGN Legend Biotech	0.00%	-7.68%	+17.61%	-6.41%	-20.21%
TGTX TG Therapeutics	0.00%	+0.03%	+4.19%	-15.47%	+104.08%
TLX Telix Pharmaceuticals	0.00%	+6.59%	+3.31%	-5.98%	+1,714,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARQT Arcutis Biotherapeutics	2.3136 of 5 stars	3.4	1.0	0.0	0.0	3.3	1.7	0.6
LEGN Legend Biotech	2.3585 of 5 stars	3.5	1.0	0.0	0.0	3.4	1.7	0.6
TGTX TG Therapeutics	3.5186 of 5 stars	2.4	1.0	0.0	3.5	1.4	2.5	1.9
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARQT Arcutis Biotherapeutics	2.83	Moderate Buy	$18.80	30.56% Upside
LEGN Legend Biotech	2.91	Moderate Buy	$76.20	125.11% Upside
TGTX TG Therapeutics	2.80	Moderate Buy	$40.80	11.60% Upside
TLX Telix Pharmaceuticals	3.00	Buy	$22.00	34.23% Upside

Current Analyst Ratings Breakdown

Latest ARQT, TGTX, LEGN, and TLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$22.00
6/5/2025	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$22.00
5/23/2025	ARQT Arcutis Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
5/14/2025	LEGN Legend Biotech	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$88.00 ➝ $71.00
5/14/2025	LEGN Legend Biotech	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$55.00 ➝ $55.00
4/22/2025	LEGN Legend Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$84.00 ➝ $84.00
4/16/2025	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
4/9/2025	ARQT Arcutis Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/8/2025	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
4/3/2025	ARQT Arcutis Biotherapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/3/2025	ARQT Arcutis Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARQT Arcutis Biotherapeutics	$196.54M	8.73	N/A	N/A	$1.35 per share	10.67
LEGN Legend Biotech	$627.24M	9.92	N/A	N/A	$5.70 per share	5.94
TGTX TG Therapeutics	$329M	17.64	$0.12 per share	300.26	$1.43 per share	25.57
TLX Telix Pharmaceuticals	$516.72M	10.73	$0.11 per share	150.18	$1.12 per share	14.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARQT Arcutis Biotherapeutics	-$140.04M	-$1.04	N/A	N/A	N/A	-60.95%	-80.66%	-32.94%	8/13/2025 (Estimated)
LEGN Legend Biotech	-$177.03M	-$0.59	N/A	N/A	N/A	-29.95%	-21.19%	-13.47%	8/8/2025 (Estimated)
TGTX TG Therapeutics	$23.38M	$0.24	152.33	36.56	N/A	10.13%	18.88%	7.05%	8/5/2025 (Estimated)
TLX Telix Pharmaceuticals	$32.93M	N/A	0.00	34.15	N/A	N/A	N/A	N/A	N/A

Latest ARQT, TGTX, LEGN, and TLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	LEGN Legend Biotech	-$0.40	-$0.07	+$0.33	-$0.27	$190.83 million	$195.05 million
5/7/2025	Q1 2025	TGTX TG Therapeutics	$0.19	$0.03	-$0.16	$0.03	$117.07 million	$120.86 million
5/6/2025	Q1 2025	ARQT Arcutis Biotherapeutics	-$0.21	-$0.20	+$0.01	-$0.20	$64.80 million	$65.85 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARQT Arcutis Biotherapeutics	0.75	3.55	3.37
LEGN Legend Biotech	0.30	5.20	5.07
TGTX TG Therapeutics	1.03	4.02	3.04
TLX Telix Pharmaceuticals	0.99	2.78	2.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARQT Arcutis Biotherapeutics	N/A
LEGN Legend Biotech	70.89%
TGTX TG Therapeutics	58.58%
TLX Telix Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ARQT Arcutis Biotherapeutics	9.40%
LEGN Legend Biotech	0.02%
TGTX TG Therapeutics	10.64%
TLX Telix Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARQT Arcutis Biotherapeutics	150	119.20 million	108.00 million	Optionable
LEGN Legend Biotech	2,609	183.76 million	183.73 million	Optionable
TGTX TG Therapeutics	290	158.76 million	141.86 million	Optionable
TLX Telix Pharmaceuticals	N/A	338.25 million	N/A	N/A

ARQT, TGTX, LEGN, and TLX Headlines

Recent News About These Companies

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - What's Next?

June 23 at 12:46 PM | marketbeat.com

Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT

June 23 at 7:15 AM | globenewswire.com

Telix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - Time to Buy?

June 20 at 2:12 PM | marketbeat.com

Telix Precision Medicine Announces AlFluor Radiochemistry Platform

June 20 at 8:00 AM | globenewswire.com

Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025

June 19, 2025 | globenewswire.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Trading Down 6.7% - Here's What Happened

June 15, 2025 | americanbankingnews.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Stock Price Down 6.7% - Time to Sell?

June 13, 2025 | marketbeat.com

Wedbush Reiterates "Outperform" Rating for Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX)

June 13, 2025 | americanbankingnews.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Up - Time to Buy?

June 12, 2025 | marketbeat.com

Telix Pharmaceuticals Limited American Depositary Shares' (TLX) "Outperform" Rating Reaffirmed at Wedbush

June 12, 2025 | marketbeat.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Down - Time to Sell?

June 6, 2025 | marketbeat.com

William Blair Has Positive Estimate for TLX FY2025 Earnings

June 6, 2025 | marketbeat.com

Wedbush Initiates Coverage of Telix Pharmaceuticals Limited - Depositary Receipt () (TLX) with Outperform Recommendation

June 5, 2025 | msn.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Up - Here's Why

June 5, 2025 | marketbeat.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Now Covered by Wedbush

June 5, 2025 | marketbeat.com

Telix Investor Day in New York City on June 11, 2025: Presenting KOLs

June 3, 2025 | globenewswire.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Up - Here's What Happened

May 31, 2025 | marketbeat.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Up 11.4% - What's Next?

May 25, 2025 | marketbeat.com

Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy

May 7, 2025 | globenewswire.com

Shareholders that Lost Money on Telix Pharmaceuticals Limited (TLX) Should Contact Levi & Korsinsky About Securities Fraud Investigation - TLX

May 7, 2025 | accessnewswire.com

ATTENTION Telix Pharmaceuticals Limited Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights

May 6, 2025 | accessnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARQT, TGTX, LEGN, and TLX Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

$14.40 +0.58 (+4.20%)

Closing price 04:00 PM Eastern

Extended Trading

$14.50 +0.10 (+0.69%)

As of 07:39 PM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Legend Biotech NASDAQ:LEGN

$33.85 -0.15 (-0.44%)

Closing price 04:00 PM Eastern

Extended Trading

$33.92 +0.06 (+0.19%)

As of 07:58 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

TG Therapeutics NASDAQ:TGTX

$36.56 +0.54 (+1.50%)

Closing price 04:00 PM Eastern

Extended Trading

$36.67 +0.11 (+0.31%)

As of 07:55 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Telix Pharmaceuticals NASDAQ:TLX

$16.39 -0.76 (-4.43%)

Closing price 04:00 PM Eastern

Extended Trading

$16.38 -0.01 (-0.06%)

As of 07:36 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time